Country websites

Creditor Relations

Our financing strategy aims

Our financing strategy aims at ensuring financial flexibility, managing financial risks and optimizing our financing cost.

Find out more about our financing strategy, major financing instruments and our credit ratings on this website.

pdf

Q3 2024 Investor
Presentation

PDF, 2 MB

Financing strategy

We ensure our financial flexibility through maintaining sufficient liquidity. Our refinancing risks are limited due to our balanced maturity profile, which is characterized by a wide range of maturities of up to 2031. Corporate bonds in euro and U.S. dollar form the basis of our mid- and long-term financing instruments. Corporate bonds in euro are issued under our €10 BN debt issuance program. For short-term financing, we use our €1.5 BN commercial paper program, Accounts Receivable Facility in U.S. dollar, and bilateral credit lines. The €2 BN Syndicated Credit Facility, signed in July 2021, serves as a backup facility.

Financing & Currency Mix

as of September 30, 2024

Does not include debt and lease liabilities which are part of liabilities directly associated with assets held for sale

Bonds and convertible bonds

Instrument Maturity/Term Amount in M ISIN Code
1.5% Bond 2018-2025 EUR 500 XS1854532949
3.75% Bond 2019-2029 USD 500 USU3149FAA76
0.625% Bond 2019-2026 EUR 600 XS2084497705
1.250% Bond 2019-2029 EUR 500 XS2084488209
1.000% Bond 2020-2026 EUR 500 XS2178769076
1.500% Bond 2020-2030 EUR 750 XS2178769159
2.375% Bond 2020-2031 USD 1,000 USU3149FAB59
1.875% Bond 2021-2026 USD 850 USU3149FAC33
3.000% Bond 2021-2031 USD 650 USU3149FAD16
3.875% Bond 2022-2027 EUR 750 XS2530444624

European Medium Term Note Program

Issuer Fresenius Medical Care AG
Program Amount € 10,000,000,000
Arranger: Deutsche Bank
Dealer: Barclays, Commerzbank, Crédit Agricole Corporate and Investment Bank, Deutsche Bank, HSBC, ING Bank, J.P. Morgan, Société Générale Corporate & Investment Banking
Fiscal and Paying Agent Deutsche Bank

Further details and Base Prospectus 

 

Commercial Paper Program

The Commercial Paper Program enables Fresenius Medical Care to issue short-term notes of up to € 1.5 billion on the money market. The issuances are made through the European Commercial Paper Program (ECP).

Issuer Fresenius Medical Care AG
Program amount ########
Arranger Commerzbank
Dealer Barclays, Commerzbank, Crédit Agricole, DZ BANK AG, ING, Landesbank Baden-Württemberg, Landesbank Hessen-Thüringen
Issuing and paying agent Commerzbank
Term Up to 2 years less 1 day

Well-balanced maturity profile1

as of September 30, 2024

On Oct. 15, 2024, Fresenius Medical Care redeemed the 400,000,000 US-Dollar bond at maturity.

1 Based on utilization of major financing instruments, excl. Commercial Paper, and other cash management lines
2 Calculations based on total financial debt, excluding Lease & Purchase Money Obligations

Net Leverage Ratio

as of September 30, 2024

1 Excl. U.S. federal relief funding and advanced payments under the CARES Act 

Rating


Standard & Poor's, Moody's and Fitch, the leading rating agencies, have assigned Fresenius Medical Care the following rating:

  Standard & Poor's Moody's Fitch
Corporate credit rating BBB- Baa3 BBB-
Outlook stable stable stable

Contact us for further information

+49 6172 609 2525

Related content